88 related items for PubMed ID: 2225560
1. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin: a two-year prospective trial.
Walker RG, Yu SH, Owen JE, Kincaid-Smith P.
Clin Nephrol; 1990 Sep; 34(3):103-7. PubMed ID: 2225560
[Abstract] [Full Text] [Related]
2. Effects of triple therapy on the progression of mesangial proliferative glomerulonephritis.
Woo KT, Edmondson RP, Yap HK, Wu AY, Chiang GS, Lee EJ, Pwee HS, Lim CH.
Clin Nephrol; 1987 Feb; 27(2):56-64. PubMed ID: 3549083
[Abstract] [Full Text] [Related]
3. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later.
Woo KT, Lee GS, Lau YK, Chiang GS, Lim CH.
Clin Nephrol; 1991 Aug; 36(2):60-6. PubMed ID: 1934661
[Abstract] [Full Text] [Related]
4. The treatment of mesangial IgA nephropathy with cyclophosphamide, dipyridamole and warfarin.
Woo KT, Lee GS.
Clin Nephrol; 1991 Apr; 35(4):184. PubMed ID: 1855324
[No Abstract] [Full Text] [Related]
5. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial.
Yoshikawa N, Honda M, Iijima K, Awazu M, Hattori S, Nakanishi K, Ito H, Japanese Pediatric IgA Nephropathy Treatment Study Group.
Clin J Am Soc Nephrol; 2006 May; 1(3):511-7. PubMed ID: 17699253
[Abstract] [Full Text] [Related]
6. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two-year prospective trial.
Bennett WM, Walker RG, Kincaid-Smith P.
Clin Nephrol; 1989 Mar; 31(3):128-31. PubMed ID: 2539929
[Abstract] [Full Text] [Related]
7. Randomized controlled trial of cyclophosphamide, warfarin and dipyridamole in idiopathic membranous glomerulonephritis.
Murphy BF, McDonald I, Fairley KF, Kincaid-Smith PS.
Clin Nephrol; 1992 May; 37(5):229-34. PubMed ID: 1606772
[Abstract] [Full Text] [Related]
8. Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment.
McIntyre CW, Fluck RJ, Lambie SH.
Clin Nephrol; 2001 Sep; 56(3):193-8. PubMed ID: 11597033
[Abstract] [Full Text] [Related]
9. Combined therapy in children and adolescents with IgA nephropathy.
Murakami K, Yoshioka K, Akano N, Takemura T, Okada M, Aya N, Hino S, Miyazato H, Yagi K, Maki S.
Nihon Jinzo Gakkai Shi; 1994 Jan; 36(1):38-43. PubMed ID: 8107307
[Abstract] [Full Text] [Related]
10. Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide.
Brodsky SV, Rovin BH, Hebert LA.
Nephrol Dial Transplant; 2012 Feb; 27(2):475-7. PubMed ID: 21948859
[No Abstract] [Full Text] [Related]
11. Combination therapy using prednisolone and cyclophosphamide slows the progression of moderately advanced IgA nephropathy.
Tsuruya K, Harada A, Hirakata H, Mitsuiki K, Johko T, Kondoh H, Takechi S, Fujishima M.
Clin Nephrol; 2000 Jan; 53(1):1-9. PubMed ID: 10661476
[Abstract] [Full Text] [Related]
12. The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy.
Shearman JD, Yin ZG, Aarons I, Smith PS, Woodroffe AJ, Clarkson AR.
Clin Nephrol; 1988 Dec; 30(6):320-9. PubMed ID: 3243041
[Abstract] [Full Text] [Related]
13. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T, Honda K, Nitta K, Yumura W, Nihei H.
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[Abstract] [Full Text] [Related]
14. A comparison of corticosteroid and warfarin therapy in IgA nephropathy with crescent formation: preliminary trial.
Kanno Y, Witt M, Okada H, Nemoto H, Sugahara S, Nakamoto H, Suzuki H.
Clin Exp Nephrol; 2003 Mar; 7(1):48-51. PubMed ID: 14586743
[Abstract] [Full Text] [Related]
15. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study.
Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group.
Am J Kidney Dis; 2006 May; 47(5):751-60. PubMed ID: 16632013
[Abstract] [Full Text] [Related]
16. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H, Muryan A, Young P, Forrester M, Iotti A, Pereyra H, Lombi F, Seminario O, Alonso M, Iotti R.
Medicina (B Aires); 2007 May; 67(5):445-50. PubMed ID: 18051227
[Abstract] [Full Text] [Related]
17. Follow-up renal biopsies in IgA nephritic patients on triple therapy.
Woo KT, Chiang GS, Lim CH.
Clin Nephrol; 1987 Dec; 28(6):304-5. PubMed ID: 3442958
[No Abstract] [Full Text] [Related]
18. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U, Ong-Ajyooth L, Parichatikanond P, Ong-Ajyooth S, Liammongkolkul S, Kanyog S.
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[Abstract] [Full Text] [Related]
19. Short- and long-term efficacy of oral cyclophosphamide and steroids in patients with membranous nephropathy and renal insufficiency. Study Group.
Branten AJ, Wetzels JF.
Clin Nephrol; 2001 Jul; 56(1):1-9. PubMed ID: 11499653
[Abstract] [Full Text] [Related]
20. [A prospective controlled study of sairei-to in childhood IgA nephropathy with focal/minimal mesangial proliferation. Japanese Pediatric IgA Nephropathy Treatment Study Group].
Yoshikawa N, Ito H, Sakai T, Takekoshi Y, Honda M, Awazu M, Ito K, Iitaka K, Koitabashi Y, Yamaoka K, Nakagawa K, Nakamura H, Matsuyama S, Seino Y, Takeda N, Hattori S, Ninomiya M.
Nihon Jinzo Gakkai Shi; 1997 Jul; 39(5):503-6. PubMed ID: 9283216
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
